These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 1788753

  • 1. [Randomized study comparing the clinical effectiveness of intravenous prostaglandin E1 and intravenous pentoxifylline in patients with Fontaine stage IIb arterial occlusive disease].
    Hepp W, von Bary S, Corovic D, Diehm C, Mühe E, Rudofsky G, Scheffler P, Trübestein G, Vogelpohl M.
    Vasa Suppl; 1991; 33():348-9. PubMed ID: 1788753
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training.
    Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H.
    Circulation; 1994 Aug; 90(2):818-22. PubMed ID: 8044953
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Experience with intravenous prostaglandin E1 in stage II b arterial occlusive disease].
    Dé P, Hepp W.
    Vasa Suppl; 1990 Aug; 30():139-41. PubMed ID: 2075565
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.
    Trübestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H, Horsch S, Kriessmann A, Maass U, Martin M.
    Vasa Suppl; 1989 Aug; 28():44-9. PubMed ID: 2692200
    [Abstract] [Full Text] [Related]

  • 10. [Walk training and drug therapy in peripheral arterial occlusive disease. A randomized, prospective, placebo-controlled double-blind study].
    Kiesewetter H, Blume J, Jung F, Gerhards M, Leipnitz G.
    Dtsch Med Wochenschr; 1987 May 29; 112(22):873-8. PubMed ID: 3556133
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Effectiveness of intravenous infusion treatment of peripheral arterial occlusive disease with Trental--results of a multicenter double-blind study].
    Rudofsky G, Haussler KF, Künkel HP, Schneider-May H, Spengel F, Symann O, Werner HJ, Rössner M.
    Vasa Suppl; 1987 May 29; 20():375-8. PubMed ID: 3321494
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of chronic occlusive arterial disease with pentoxifylline: changes in clinical and haemodynamic parameters.
    Schweiger H, Ortmeier CJ.
    Pharmatherapeutica; 1989 May 29; 5(5):298-304. PubMed ID: 2526340
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
    Chopra HK, Chopra KL, Aggarwal KK, Parashar SK.
    J Med; 1988 May 29; 19(2):89-107. PubMed ID: 3049876
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.